RxDoctor Payments Data

Graham Glass, MD

Neurology · San Francisco, CANPI 1881671907

Payments from drug & device makers

$4,051in general payments, 2019–2025

Across 40 payments — averaging $101.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Medtronic$1K
  • Amneal Pharmaceuticals LLC$47
  • AbbVie$35
  • Acadia Pharmaceuticals Inc$18
  • Bayer$13
$6,000in research payments, 2019–2025

Across 2 payments — averaging $3000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$6K

What the payments were for

  • Travel & lodging$2,24755%
  • Food & beverage$1,80445%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific15$2,577
Medtronic(2 entities)19$1,362
Amneal Pharmaceuticals LLC2$47
AbbVie1$35
Acadia Pharmaceuticals Inc2$18
Bayer1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,051 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$260,160
Medicare patients
581
Services billed
15,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate16$180,158
RytaryCarbidopa/Levodopa106$175,622
Carbidopa-LevodopaCarbidopa/Levodopa332$24,434
LinzessLinaclotide12$17,018
Carbidopa-Levodopa ErCarbidopa/Levodopa123$9,669
Entacapone31$6,559
Rasagiline Mesylate35$3,849
Pramipexole DihydrochloridePramipexole Di-Hcl86$2,975
AmantadineAmantadine Hcl49$1,352
Escitalopram Oxalate120$1,346
Ropinirole Hcl18$1,159
Propranolol Hcl35$1,109
Midodrine Hcl12$930
Gabapentin48$902
Primidone27$679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$18$180,15816 claims
Amneal Pharmaceuticals LLCRytary$47$175,622106 claims
AbbVieLinzess$35$17,01812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,996 neurology providers in California.

Other neurology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →